1,4-Dioxaspiro[4,5]dec-7-en-8-boronic acid pinacol ester, identified by CAS 680596-79-6, is a boronic ester building block used primarily in organic synthesis and pharmaceutical research. I describe it as a protected boron-containing cyclohexene intermediate with a spirocyclic 1,3-dioxolane structure. Its main value is the combination of a reactive boronic ester handle, an alkene, and a ketone-protecting acetal motif in one molecule. Researchers commonly evaluate it for carbon–carbon bond-forming chemistry, especially Suzuki–Miyaura coupling and related intermediate-development work.
For more information, please visit our website.
This material is a research and synthesis reagent rather than an active pharmaceutical ingredient. Its suitability depends on the intended reaction, required purity, analytical data, scale, and handling conditions. At Maison Chemical, I support qualified buyers by helping them confirm identity, documentation, packaging, and supply requirements before they place a purchase order.
The name contains several important structural details. “Dioxaspiro[4,5]dec” indicates a spirocyclic framework in which two rings share one carbon atom, while “7-en” identifies an alkene within the cyclic system. The “8-boronic acid pinacol ester” portion indicates that boron is present as a pinacol-protected boronate rather than as a free boronic acid.
From a synthetic perspective, the molecule contains three useful features: a boronic ester for cross-coupling, a carbon–carbon double bond for further functionalization, and a cyclic acetal that can serve as a protected carbonyl equivalent. The acetal is commonly considered a ketone-protection strategy, but deprotection conditions must be selected carefully because strong aqueous acid may affect other sensitive groups in a larger molecule.
| Item | Information |
|---|---|
| Product name | 1,4-Dioxaspiro[4,5]dec-7-en-8-boronic acid pinacol ester |
| CAS number | 680596-79-6 |
| Compound class | Protected cyclic boronic ester and synthetic intermediate |
| Key functional groups | Boronate ester, alkene, and cyclic acetal |
| Primary use | Research, medicinal chemistry, and organic synthesis |
The boronic ester is the most prominent reactive feature. Under suitable palladium-catalyzed Suzuki–Miyaura conditions, it may participate in coupling with an appropriate aryl or heteroaryl halide or related electrophile. The exact outcome depends on the catalyst, base, solvent, temperature, substrate compatibility, and protection of the boronate during the reaction.
I recommend treating the boronate as a versatile reaction handle, not as a guarantee of successful conversion in every system. Pinacol protection generally improves the practical handling of boron reagents compared with some free boronic acids, but hydrolysis, protodeboronation, or incomplete conversion can still occur under unsuitable conditions.
The 1,3-dioxolane ring can be useful when a carbonyl group must remain masked during earlier synthetic steps. After the desired transformations are complete, a chemist may investigate deprotection to regenerate the corresponding ketone. Because deprotection behavior varies with substrate and conditions, I advise buyers to confirm compatibility through small-scale experiments rather than relying only on the name or structure.
The cyclic alkene offers another point of chemical diversification. Depending on the project, researchers may explore hydrogenation, oxidation, addition, or other alkene transformations. These reactions can be affected by the boronate and acetal groups, so chemoselectivity should be assessed experimentally.
This compound is relevant to medicinal chemistry programs that need compact, multifunctional intermediates for analog generation. A research team may use the boronate to attach an aromatic or heteroaromatic fragment, then modify the alkene or remove the acetal protection in later steps. Such a sequence can help create structural diversity from a common intermediate, although the practical route must be validated for each target series.
It can also support process-development and route-screening activities. In these settings, buyers may compare catalyst systems, bases, solvents, work-up procedures, and purification methods. The compound may be ordered as a small research sample first and then evaluated for larger-scale availability once conversion, selectivity, and isolation performance are understood.
Academic laboratories, contract research organizations, and pharmaceutical intermediate developers may all consider this material when a protected cyclic boronate is needed. I do not recommend presenting it as a finished drug substance, a biologically active ingredient, or a product with established clinical use. Its documented role is as a chemical building block for research and synthesis.
Maison Chemical contains other products and information you need, so please check it out.
In commercial purchasing, the most important differences may relate to purity, analytical documentation, batch size, packaging, and delivery schedule rather than to different “types” of the molecule. Buyers should confirm whether they need a research-grade sample, a higher-volume intermediate, or a batch supported by expanded quality documentation. The correct option depends on the stage of the project.
A typical initial evaluation may involve a small sample such as 100 mg, while route development can require gram-level or larger quantities. These quantities are planning examples, not universal package specifications. I advise buyers to request the available pack sizes and confirm whether the same analytical profile can be maintained across different scales.
| Specification area | What buyers should confirm |
|---|---|
| Identity | CAS number, chemical name, structure, and analytical confirmation |
| Purity | Assay method, reported purity, and major impurity profile |
| Analytical package | Available HPLC, NMR, LC-MS, GC, or other applicable data |
| Physical form | Appearance, batch consistency, and handling instructions |
| Supply terms | Pack size, MOQ, lead time, export documents, and shipping conditions |
First, I ask whether the buyer intends to perform Suzuki coupling, protect or deprotect a carbonyl equivalent, modify the alkene, or use the compound in another route. This determines which impurities and stability concerns are most important. A material suitable for exploratory medicinal chemistry may not automatically meet the requirements of a controlled process-development campaign.
I recommend checking the product name and CAS number against the supplier’s certificate of analysis and analytical spectra. Buyers should pay particular attention to evidence for the boronate, the spirocyclic framework, and the absence of unexpected starting materials or regioisomers. If the route is sensitive, it is reasonable to request representative batch data before approving a larger order.
For an initial reaction screen, a chemist may select a 1 mmol starting scale and compare several catalyst or base conditions. A screening window of 12–24 hours can be used as a practical planning range, but it is not a guaranteed reaction time for CAS 680596-79-6. Conversion, selectivity, isolation yield, and boronate stability should be measured rather than assumed.
Because boronic esters and protected multifunctional intermediates may be sensitive to moisture, heat, or incompatible chemicals, I advise buyers to follow the supplier’s label and safety data sheet. The material should be handled by trained personnel using appropriate laboratory controls. Storage requirements should be confirmed for the specific batch and packaging configuration supplied.
At Maison Chemical, I provide B2B support for customers evaluating 1,4-Dioxaspiro[4,5]dec-7-en-8-boronic acid pinacol ester CAS 680596-79-6 for pharmaceutical and chemical research. I can help clarify product identity, available quantity, documentation, packaging, and export requirements. Where project information is available, I can also help organize a quotation around sample evaluation, repeat supply, or larger intermediate requirements.
I use conservative communication when a specification is not confirmed. Rather than presenting unverified purity, stability, certification, or delivery claims as fixed facts, I recommend confirming them against the current batch documents and commercial quotation. This approach helps purchasing, quality, and research teams make decisions based on evidence.
Yes, this compound may be relevant if your project requires a multifunctional cyclic intermediate containing a protected carbonyl equivalent, an alkene, and a boronic ester for further synthetic elaboration. Its strongest value is route flexibility, especially when researchers want to introduce an aryl or heteroaryl group through cross-coupling and retain additional functionality for later steps. Its suitability still depends on the exact reaction design and the quality requirements of your project.
As the next step, I recommend sharing your target quantity, intended application, required purity, delivery destination, and documentation expectations with Maison Chemical. I can then help confirm available supply information and prepare a B2B quotation for your evaluation. This gives your purchasing and technical teams a clear basis for deciding whether CAS 680596-79-6 fits the next stage of your synthesis program.
If you want to learn more, please visit our website 1,4-Dioxaspiro[4,5]dec-7-en-8-boronic acid pinacol ester CAS 680596-79-6.